RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform Rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- Netflix raises prices in Germany and Austria, Citi comments
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Baird Upgrades Biogen (BIIB) to Outperform
October 22, 2014 12:45 PM EDTBaird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $382.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $326.77 yesterday.
... MoreBiogen Idec (BIIB) Says Tecfidera Patient Who Died had Low White Blood Cell Counts
October 22, 2014 11:52 AM EDTBiogen Idec Inc. (BIIB) is seeing some unnecessary weakness Wednesday following Q3 results and the company's conference call.
Earlier, the WSJ cited the company as saying it confirmed a... More
Biogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)
October 22, 2014 10:52 AM EDTDeutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $430. Analyst Robyn Karnauskas commented on recent weakness and compared the stock to Celgene (NASDAQ: CELG). Overall, she is positive on both stocks.
"Biogen is trading weak post earnings due to 1) slower sequential revenue growth and 2) One PML case with Tecfidera disclosed on todays call. While we note that there is a good risk/reward... More
Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook
October 22, 2014 7:06 AM EDTBiogen Idec (NASDAQ: BIIB) reported Q3 EPS of $3.80, $0.31 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.48 billion.
The third quarter was a period of significant achievement as we continued to make progress against our... More
